FOVOCIP研究:磷霉素对比环丙沙星预防血液病患者发热性中性粒细胞减少的多中心随机试验——疗效与微生物学安全性
FOVOCIP是一项III期随机、对照、开放标签、平行组、1:1分配的多中心临床试验,旨在证明口服磷霉素对比口服环丙沙星在急性白血病或造血细胞移植受者中预防发热性中性粒细胞减少的非劣效性。计划每周进行监测培养以检测肠道定植,并分析预防前后粪便微生物组变化,以评估两种药物策略的微生物学安全性。
要点
- 磷霉素对比环丙沙星预防血液病患者发热性中性粒细胞减少的III期非劣效性随机试验。
- 计划每周监测培养检测肠道多重耐药革兰阴性杆菌定植。
- 将分析预防前后粪便微生物组变化以评估微生物学安全性。
核心结论
- 该试验将为高危血液病患者发热性中性粒细胞减少预防中环丙沙星的替代药物提供疗效证据。
研究设计与样本
- III期随机、对照、开放标签、平行组临床试验,1:1比例,旨在证明口服磷霉素对比口服环丙沙星预防急性白血病或造血细胞移植受者发热性中性粒细胞减少的非劣效性。
- 计划每周进行监测培养以检测肠道定植,并分析预防开始和结束时粪便微生物组变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multidrug-resistant Gram-negative bacterial (MRGNB) infections represent a major public health threat. Cancer patients and, among them, hematological patients are most vulnerable to these infections. Gut colonization by MRGNB is a common phenomenon occurring during hospitalization and chemotherapy exposure. In the neutropenic phase that occurs after chemotherapy, MRGNB translocation occurs increasing patient's mortality. Fluoroquinolone prophylaxis with ciprofloxacin or levofloxacin efficacy is now being questioned due to the increase of incidence in MRGNB. METHODS: A phase III randomized, controlled, clinical trial, open-label parallel-group with a 1:1 ratio, aimed to demonstrate the non-inferiority of oral fosfomycin versus oral ciprofloxacin for febrile neutropenia prevention in patients with acute leukemia (AL) or hematopoietic cell transplant (HSC) receptors. Weekly surveillance cultures are planned to detect gut colonization. Changes in fecal microbiome at the beginning and end of prophylaxis will also be analyzed. DISCUSSION: This trial will provide evidence of the efficacy of an alternative drug to ciprofloxacin for febrile neutropenia prevention in high-risk hematological patients. The battery of planned microbiological studies will allow us to evaluate prospectively the microbiological safety of both pharmacological strategies in terms of the selection of MRGNB occurring in each arm. In addition, valuable information on the way in which each drug changes the fecal microbiome of the patients throughout the treatment will be generated. TRIAL REGISTRATION: Clinical trials NCT05311254, Registered on 5 April 2022, https://clinicaltrials.gov/ct2/show/NCT05311254?term=FOVOCIP&cntry=ES&draw=2&rank=1 . PROTOCOL VERSION: 3.0, dated 20 May 2022.
引用
- Moreno AF, Lavín-Alconero L, de Ugarriza PL, et al. FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety. Trials. 2023. PMID: 37891616. doi:10.1186/s13063-023-07702-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。